Advances in the application of programmed death-1/programmed death-ligand 1 inhibitors in the treatment of hepatocellular carcinoma
DOI:10.3969/j.issn.1001-5256.2021.02.040
- VernacularTitle:程序性细胞死亡受体1及其配体抑制剂在肝细胞癌治疗中的应用进展
- Author:
Zhaoyue WANG
1
;
Lai WEI
;
Yuan HUANG
Author Information
1. Hepato-pancreato-biliary Center, Department of Hepatology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China
- Publication Type:Research Article
- Keywords:
Carcinoma, Hepatocellular;
Immunotherapy;
Immune Checkpoint Inhibitor;
Programmed Cell Death 1 Receptor
- From:
Journal of Clinical Hepatology
2021;37(2):437-443
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is one of the most common malignancies in China, and due to the lack of specific symptoms, more than half of these patients are in the advanced stage at the time of initial diagnosis. Targeted therapy and systemic chemotherapies are the main treatment methods for advanced HCC with limited efficacy. In recent years, immunotherapy has been developed rapidly. This article introduces the current status of the immune checkpoint inhibitors, programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors, in the treatment of HCC, summarizes the latest data of several clinical trials, and analyzes the safety and efficacy of monotherapy and combination therapy. The analysis shows that immunotherapy has become one of the important methods for systemic treatment, and combination therapy can significantly improve the outcome of HCC with a manageable safety profile, which is an important direction for future development.
